Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 12

Results For "formulation"

1015 News Found

FDA flags uncertainty over PFAS in cosmetics, calls for more research
News | January 05, 2026

FDA flags uncertainty over PFAS in cosmetics, calls for more research

Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety


Zydus Group elevates Dr. Tushar Nahata to Vice President
People | January 04, 2026

Zydus Group elevates Dr. Tushar Nahata to Vice President

His professional background also includes key experience at Matrix Labs and Sun Pharma


Govt. issues draft amendment to remove cough syrups from Schedule K
Policy | January 01, 2026

Govt. issues draft amendment to remove cough syrups from Schedule K

Once finalized, cough syrups will no longer be available for over-the-counter sale


SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer
Clinical Trials | December 29, 2025

SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer

The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38


CPHI & PMEC India 2025 ignites pharma innovation and partnerships
News | December 29, 2025

CPHI & PMEC India 2025 ignites pharma innovation and partnerships

For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows


Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist
News | December 29, 2025

Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist

Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals


Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
Drug Approval | December 26, 2025

Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA

These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products


FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
Drug Approval | December 23, 2025

FDA go-ahead to Roche’s one-minute follicular lymphoma therapy

Full approval will depend on verification of clinical benefit in a confirmatory trial


Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
Clinical Trials | December 23, 2025

Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug

The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa


Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries
News | December 23, 2025

Biocon inks out-licensing agreement with Ajanta to market Semaglutide in 26 countries

Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia